# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Locke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN001-SYN-TD
- Date: 1692-06-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Prudence Hartwell-Osei, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Twelve-week asthma review with repeat spirometry. **S**

## History of present illness

Mr. Locke returns twelve weeks after starting budesonide-formoterol as maintenance and reliever. He finished the eight-week pulmonary rehabilitation program, attending all 16 sessions, and walks 30 minutes five days a week. He needs three or four extra inhalations a week, mostly after his days in the city, and woke at night with cough once in the past month. He has had no flare and no oral corticosteroids. The dose counter matches his diary, with about one missed evening dose a fortnight. He has had no hoarseness or sore mouth. His home peak flow is best at 440 L/min in the mornings and falls to about 360 after a city day. The open fires stay out; a small air monitor in his study usually reads below 10 ug/m3 of PM2.5. He has spent two or three days a month in the city and stayed away during an air quality alert in May. **S**

| Element | Detail |
|---|---|
| Reliever use | Three or four extra inhalations a week |
| Night waking | Once in the past month |
| Adherence | About one missed maintenance dose a fortnight; dose counter agrees |
| Rehabilitation | 16 of 16 sessions completed |
| Peak flow | Personal best 440 L/min |
| Asthma Control Test | 19, up from 13 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Breathless on steep hills; some cough and tightness after city days; no hemoptysis |
| Ears, nose, mouth, and throat | Negative | No hoarseness, sore mouth, or thrush |
| Cardiovascular | Negative | No palpitations, tremor, or ankle swelling |

3 systems reviewed. **S**

## Current medications

- Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day **S**
- Tiotropium 2.5 mcg/actuation soft-mist inhaler, two inhalations once daily (add-on long-acting muscarinic antagonist, GINA step 5) **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/72 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 62.8 kg; BMI 19.8 kg/m². All vital signs are synthetic.

Asthma Control Test: 19; FEV1 before bronchodilator: 2.46 L (low); FEV1 percent predicted (before bronchodilator): 73% (low); FEV1 after bronchodilator: 2.58 L (low); FVC after bronchodilator: 4.12 L; FEV1/FVC after bronchodilator: 0.63 (low); FeNO: 22 [ppb]; Six-minute walk distance: 505 m. All results are synthetic.

## Change since baseline

- Asthma Control Test: 12 at baseline, 19 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 62.8 kg |
| Mouth | No oral candidiasis |
| Respiratory | Good air entry; a few end-expiratory wheezes on forced expiration; oxygen saturation 97 percent |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Asthma with persistent airflow limitation, type 2 phenotype** (J45.40). Much better but not yet well controlled: Asthma Control Test 19 and reliever use three or four times a week, with no flares. FEV1 2.46 L before bronchodilator (73 percent predicted), up 350 mL, and 2.58 L after, with a post-bronchodilator FEV1/FVC of 0.63, still below the lower limit of normal: a large improvement, but airflow limitation persists. FeNO has fallen from 41 to 22 ppb, showing that he is taking the inhaled corticosteroid and that his type 2 inflammation has responded. Adherence and technique are good. The six-minute walk improved by 75 m after rehabilitation. Because residual symptoms come with persistent airflow limitation and low FeNO, adding tiotropium (GINA step 5 add-on LAMA) is preferred over a higher corticosteroid dose; a biologic is not indicated. **S**
   - Add tiotropium 2.5 mcg soft-mist inhaler, two inhalations once daily; technique taught today.
   - Continue budesonide-formoterol two inhalations twice daily plus one as needed, no more than 12 a day.
   - Action plan updated with peak-flow zones from his best of 440 L/min: green 352 or more, yellow 220 to 351, red below 220.
   - Keep up the walking program.
   - Review at his preventive visit in three months and with an Asthma Control Test at four months.
2. **Exposure to air pollution and indoor solid-fuel smoke** (Z77.110). Indoor smoke removed; outdoor exposure reduced by planning around alerts. City days still bring symptoms. **S**
   - Continue the exposure plan; keep city visits to days with an air quality index below 100.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test | Every visit | Completed today | 19, up from 13; not yet well controlled (20 or more) |
| Imaging | Spirometry before and after bronchodilator | At diagnosis, 3 to 6 months after starting treatment, then every 1 to 2 years | Completed today | FEV1 2.46 L before (73 percent predicted) and 2.58 L after bronchodilator; FVC 4.12 L after; FEV1/FVC 0.63 after, still below the lower limit of normal; next in one to two years |
| Imaging | FeNO | To monitor inhaled-corticosteroid response | Completed today | 22 ppb, down from 41 |
| Imaging | Six-minute walk test | Before and after pulmonary rehabilitation | Completed today | 505 m, up 75 m from 430 m |
| Imaging | Home peak expiratory flow | Daily for moderate to severe asthma, then with symptoms | Completed today | Diary reviewed: personal best 440 L/min; about 360 after city days |
| Examination | Inhaler technique with his own devices | Every visit | Completed today | Budesonide-formoterol technique correct; tiotropium soft-mist inhaler taught today, correct by teach-back |
| Medication safety | Adherence and reliever use | Every visit | Completed today | About one missed maintenance dose a fortnight by dose counter and diary; three or four as-needed inhalations a week |
| Medication safety | Inhaled-corticosteroid side effects (hoarseness, thrush) | Every visit | Completed today | None |
| Survey | Exacerbation history | Every visit | Completed today | None since treatment began; no oral corticosteroids |
| Self-management | Trigger and exposure review: indoor solid-fuel smoke, outdoor air pollution and air quality alerts, tobacco and vaping, occupational exposures, allergens | Every visit | Completed today | Open fires out of use; indoor PM2.5 on his monitor usually below 10 ug/m3; HEPA air cleaners running; city trip postponed during an air quality alert |
| Self-management | Smoking and vaping status | Every visit | Completed today | Never smoker; no vaping; no secondhand smoke |
| Self-management | Written asthma action plan | Every visit and after every flare | Completed today | Updated with peak-flow zones: green 352 or more, yellow 220 to 351, red below 220 L/min |
| Medication safety | Step-up and step-down assessment | Every visit | Completed today | Not well controlled on step 4 with good adherence and technique: step up by adding tiotropium (step 5) |
| Referral | Pulmonary rehabilitation | For persistent breathlessness or reduced exercise capacity | Completed today | Program completed; home walking program to maintain the gain |
| Self-management | Vaccination status | Yearly | Up to date | PCV20 given at the diagnosis visit; influenza, COVID-19, and RSV vaccines due in the autumn |
| Medication safety | Biologic candidacy | When asthma is severe and uncontrolled despite optimized step 4 to 5 treatment with confirmed adherence and technique | Not indicated | No exacerbations needing oral corticosteroids and not uncontrolled on optimized treatment |

## Goal progress

- Cause of the cough and breathlessness established by the second visit. Outcome by 1692-03-26: Asthma with persistent airflow limitation confirmed by spirometry, FeNO, eosinophils, DLCO, and CT; tuberculosis, alpha-1 antitrypsin deficiency, and heart failure excluded. **S**
- Asthma well controlled (Asthma Control Test 20 or more) with no flare needing oral corticosteroids. In progress; target 1693-03-31. **S**
- No indoor solid-fuel smoke and less outdoor pollution exposure. In progress; target 1693-03-31. **S**
- Six-minute walk distance improved by at least 30 m after pulmonary rehabilitation. Outcome by 1692-06-18: 430 m before and 505 m after an eight-week program. **S**

## Medication changes

- Started: Tiotropium 2.5 mcg/actuation soft-mist inhaler, two inhalations once daily (add-on long-acting muscarinic antagonist, GINA step 5) **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026), Aether Forge
- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022), European Respiratory Society and American Thoracic Society
- Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023), American Thoracic Society
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;208(4):e7-e26)
- WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021), World Health Organization
- Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020), European Respiratory Society
- AQI Basics (2026), United States Environmental Protection Agency (AirNow)
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Preventive visit in three months, with a brief asthma check; asthma review with an Asthma Control Test in four months. **S**
- Next scheduled visit 1692-09-17: preventive health visit at 60. **S**
